Compagnie Lombard Odier S Cm A Biomarin Pharmaceutical Inc Transaction History

Compagnie Lombard Odier S Cm A

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$74.28 - $92.69 $8,319 - $10,381	-112 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $200,875 - $234,750	-2,500 Reduced 95.71%	112 $10,000
Q1 2019 May 13, 2019	BUY	$84.2 - $98.62 $210,500 - $246,550	2,500 Added 2232.14%	2,612 $232,000
Q4 2017 Feb 13, 2018	SELL	$80.76 - $95.13 $64,608 - $76,104	-800 Reduced 87.72%	112 $10,000
Q3 2017 Nov 14, 2017	SELL	$80.6 - $94.95 $245,829 - $289,597	-3,050 Reduced 76.98%	912 $84,000
Q2 2017 Aug 14, 2017	BUY	N/A	3,962	3,962 $360,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.